Skip to main content
SpringerLink
Log in

Bisphosphonates for Osteoporosis

  • Chapter
  • First Online:
Medicines For Women

Abstract

Bisphosphonates are among the most widely used medicines for the treatment of bone diseases. They are generally well tolerated, serious adverse events are rare and the risk-benefit risk profile in osteoporotic patients is overwhelmingly favourable in most better option.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abrahamsen B (2010) Adverse effects of bisphosphonates. Calcif Tissue Int 86:421–435

    Article  CAS  PubMed  Google Scholar 

  • Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid- induced osteoporosis. N Engl J Med 337:382–387

    Article  CAS  PubMed  Google Scholar 

  • Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211

    Article  CAS  PubMed  Google Scholar 

  • Adachi JD, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial. Calcif Tissue Int 89:427–433

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881–889

    Article  CAS  PubMed  Google Scholar 

  • Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67:61–70

    Article  PubMed  Google Scholar 

  • Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  CAS  PubMed  Google Scholar 

  • Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

    Article  CAS  PubMed  Google Scholar 

  • Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszu E, Lane JM, Lorenc R, Makitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424–1432

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D (2007) Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7:144–148

    CAS  PubMed  Google Scholar 

  • Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694

    Article  CAS  PubMed  Google Scholar 

  • Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199

    Article  CAS  PubMed  Google Scholar 

  • Bounameaux HM, Schifferli J, Montani J-P, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet i:471

    Article  Google Scholar 

  • Boyce BF, Smith L, Fogelman I, Johnston E, Ralston SH, Boyle IT (1984) Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease. Lancet 1:821–824

    Article  CAS  PubMed  Google Scholar 

  • Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve- month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318

    Article  CAS  PubMed  Google Scholar 

  • Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119–127

    Article  CAS  PubMed  Google Scholar 

  • Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97

    Article  CAS  PubMed  Google Scholar 

  • Coxon FP, Helfrich MH, Van’t Hof RJ, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467–1476

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  • Delmas PD, Recker RR, Chesnut CH III, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798

    Article  CAS  PubMed  Google Scholar 

  • Djokanovic N, Klieger-Grossmann C, Koren G (2008) Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30:1146–1148

    PubMed  Google Scholar 

  • Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292

    Article  CAS  PubMed  Google Scholar 

  • Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223

    Article  CAS  PubMed  Google Scholar 

  • Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33

    Article  CAS  PubMed  Google Scholar 

  • Fleisch HA (2000) Bisphosphonates in bone disease: from laboratory to the patient, 4th edn. Academic Press, San Diego

    Google Scholar 

  • Fleisch H, Russell RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264

    Article  CAS  PubMed  Google Scholar 

  • Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR (1981) The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3:289–300

    Article  CAS  PubMed  Google Scholar 

  • Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895–1900

    CAS  PubMed  Google Scholar 

  • Francis MD, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266

    Article  CAS  PubMed  Google Scholar 

  • Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367

    Article  CAS  PubMed  Google Scholar 

  • Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201–2210

    Article  CAS  PubMed  Google Scholar 

  • Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141:1365–1370

    Article  CAS  PubMed  Google Scholar 

  • Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 25:2251–2255

    Article  CAS  PubMed  Google Scholar 

  • Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150

    Article  CAS  PubMed  Google Scholar 

  • Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

    Article  CAS  PubMed  Google Scholar 

  • Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237–245

    Article  CAS  PubMed  Google Scholar 

  • Hellmeyer L, Kuhnert M, Ziller V, Schmidt S, Hadji P (2007) The use of i. v. bisphosphonate in pregnancy-associated osteoporosis–case study. Exp Clin Endocrinol Diabetes 115:139–142

    Article  CAS  PubMed  Google Scholar 

  • Idris AI, Rojas J, Greig IR, van’t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191–201

    Article  CAS  PubMed  Google Scholar 

  • Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro CN, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA (2014) Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol 166:109–117

    Article  CAS  PubMed  Google Scholar 

  • Janner M, Muhlbauer RC, Fleisch H (1991) Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int 49:280–283

    Article  CAS  PubMed  Google Scholar 

  • Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Article  PubMed  Google Scholar 

  • Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430

    Article  CAS  PubMed  Google Scholar 

  • Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443

    Article  CAS  PubMed  Google Scholar 

  • Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589

    Article  CAS  PubMed  Google Scholar 

  • Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

    Article  CAS  PubMed  Google Scholar 

  • Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD (1998) United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 48:1161–1162

    CAS  PubMed Central  PubMed  Google Scholar 

  • McClung MR, Guesens P, Miller PD, Zippel H, Roux C, Roux C, Adami S, Fogelman I, Diamond T, Meunier PJ, Wasnich RD, Greenwald M, Kaufman JM, Chestnut CH III, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

    Article  CAS  PubMed  Google Scholar 

  • Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689–3698

    CAS  PubMed  Google Scholar 

  • Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396–402

    CAS  PubMed  Google Scholar 

  • Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627

    Article  CAS  PubMed  Google Scholar 

  • Novince CM, Ward BB, McCauley LK (2009) Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 189:275–283

    Article  PubMed  Google Scholar 

  • Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578–579

    Article  CAS  PubMed  Google Scholar 

  • O’Sullivan SM, Grey AB, Singh R, Reid IR (2006) Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 17:1008–1012

    Article  PubMed  Google Scholar 

  • Oswald AJ, Berg J, Milne G, Ralston SH (2014) Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice. Calcif Tissue Int 94:176–182

    Article  CAS  PubMed  Google Scholar 

  • Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461–468

    Article  CAS  PubMed  Google Scholar 

  • Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315–328

    Article  CAS  PubMed  Google Scholar 

  • Ralston SH, Kou TD, Wick-Urban B, Steinbuch M, Masud T (2010) Risk of upper gastrointestinal tract events in risedronate users switched to alendronate. Calcif Tissue Int 87:298–304

    Article  CAS  PubMed  Google Scholar 

  • Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 31:2685–2691

    Article  CAS  PubMed  Google Scholar 

  • Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24:1282–1289

    Article  CAS  PubMed  Google Scholar 

  • Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  CAS  PubMed  Google Scholar 

  • Reginster JY, Adami S, Lakatos P, Grennwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2005a) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 65(5):654–661

    Article  PubMed  Google Scholar 

  • Reginster JY, Seeman E, de Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz CM, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005b) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90:2816–2822

    Article  CAS  PubMed  Google Scholar 

  • Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013

    Article  CAS  PubMed  Google Scholar 

  • Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3–S18

    Article  CAS  PubMed  Google Scholar 

  • Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263

    Article  CAS  PubMed  Google Scholar 

  • Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–4387

    Article  CAS  PubMed  Google Scholar 

  • Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S (2013) Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab 98:557–563

    Article  CAS  PubMed  Google Scholar 

  • Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanisms of action of bisphosphonates. Bone 24:73S–79S

    Article  CAS  PubMed  Google Scholar 

  • Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151

    Article  CAS  PubMed  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Google Scholar 

  • Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19

    Article  CAS  PubMed  Google Scholar 

  • Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H (1970) The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:183–196

    Article  CAS  PubMed  Google Scholar 

  • Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759

    Article  CAS  PubMed  Google Scholar 

  • Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299

    Article  CAS  PubMed  Google Scholar 

  • Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355

    Article  CAS  PubMed  Google Scholar 

  • Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology 81:298–305

    Article  CAS  PubMed  Google Scholar 

  • Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018

    Article  CAS  PubMed  Google Scholar 

  • Sansom LN, Necciari J, Thiercelin JF (1995) Human pharmacokinetics of tiludronate. Bone 17:479S–483S

    Article  CAS  PubMed  Google Scholar 

  • Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095–2105

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737

    Article  CAS  PubMed  Google Scholar 

  • Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1–12

    CAS  Google Scholar 

  • Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  • Shenker NG, Shaikh MF, Jawad AS (2010) Transient osteoporosis associated with pregnancy: use of bisphosphonate in treating a lactating mother. BMJ Case Rep doi:10.1136/bcr.07.2009.2112

  • Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139

    Article  CAS  PubMed  Google Scholar 

  • Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis [see comments]. N Engl J Med 322:1265–1271

    Article  CAS  PubMed  Google Scholar 

  • Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262–270

    Article  CAS  PubMed  Google Scholar 

  • Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967–975

    Article  PubMed  Google Scholar 

  • van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129–137

    Article  CAS  PubMed  Google Scholar 

  • van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 37:87–94

    Article  PubMed  Google Scholar 

  • Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285

    Article  CAS  PubMed  Google Scholar 

  • Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79

    Article  CAS  PubMed  Google Scholar 

  • Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008a) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev doi:10.1002/14651858.CD001155.pub2

  • Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008b) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev doi:10.1002/14651858.CD004523.pub3.

  • Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    Article  CAS  PubMed  Google Scholar 

  • Wysowski DK, Chang JT (2005) Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165:346–347

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone and Rheumatology Research Group, University of Edinburgh, Edinburgh, EH4 2XU, UK

    Stuart Ralston

Authors
  1. Stuart Ralston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart Ralston .

Editor information

Editors and Affiliations

  1. Dean’s Department, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Mira Harrison-Woolrych

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ralston, S. (2015). Bisphosphonates for Osteoporosis. In: Harrison-Woolrych, M. (eds) Medicines For Women. Adis, Cham. https://doi.org/10.1007/978-3-319-12406-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12406-3_12

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-12405-6

  • Online ISBN: 978-3-319-12406-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation